Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Patrick S Parfrey

Showing results (131-140 of 157) with videos related to

Pageof 16
Sort By:
American Journal of Medical Genetics. Part A|January 8, 2005
Clinical and genetic epidemiology of Bardet-Biedl syndrome in Newfoundland: a 22-year prospective, population-based, cohort studySusan J Moore, Jane S Green, Yanli Fan, et al.
American Journal of Human Genetics|March 4, 2008
Arrhythmogenic right ventricular cardiomyopathy type 5 is a fully penetrant, lethal arrhythmic disorder caused by a missense mutation in the TMEM43 geneNancy D Merner, Kathy A Hodgkinson, Annika F M Haywood, et al.
American Journal of Kidney Diseases : the Official Journal of the National Kidney Foundation|November 20, 2012
Hemoglobin stability in patients with anemia, CKD, and type 2 diabetes: an analysis of the TREAT (Trial to Reduce Cardiovascular Events With Aranesp Therapy) placebo armHicham Skali, Julie Lin, Marc A Pfeffer, et al.
Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association|April 25, 2023
Vadadustat for treatment of anemia in patients with dialysis-dependent chronic kidney disease receiving peritoneal dialysisMark J Sarnak, Rajiv Agarwal, Neil Boudville, et al.
The Journal of Clinical Endocrinology and Metabolism|October 11, 2013
The clinical course of treated hyperparathyroidism among patients receiving hemodialysis and the effect of cinacalcet: the EVOLVE trialPatrick S Parfrey, Glenn M Chertow, Geoffrey A Block, et al.
The New England Journal of Medicine|November 6, 2012
Effect of cinacalcet on cardiovascular disease in patients undergoing dialysis, Glenn M Chertow, Geoffrey A Block, et al.
Hemodialysis International. International Symposium on Home Hemodialysis|November 14, 2015
Cinacalcet, dialysate calcium concentration, and cardiovascular events in the EVOLVE trialPatrick H Pun, Safa Abdalla, Geoffrey A Block, et al.
Journal of the American Heart Association|November 19, 2014
Effects of cinacalcet on atherosclerotic and nonatherosclerotic cardiovascular events in patients receiving hemodialysis: the EValuation Of Cinacalcet HCl Therapy to Lower CardioVascular Events (EVOLVE) trialDavid C Wheeler, Gerard M London, Patrick S Parfrey, et al.
International Journal of Cancer|December 21, 2010
Cancer risks for monoallelic MUTYH mutation carriers with a family history of colorectal cancerAung Ko Win, Sean P Cleary, James G Dowty, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 6, 2005
High frequency of hereditary colorectal cancer in Newfoundland likely involves novel susceptibility genesMichael O Woods, Angela J Hyde, Fiona K Curtis, et al.
Pageof 16

Showing results (131-140 of 157) with videos related to

Sort By:
Pageof 16
American Journal of Medical Genetics. Part A|January 8, 2005
Clinical and genetic epidemiology of Bardet-Biedl syndrome in Newfoundland: a 22-year prospective, population-based, cohort studySusan J Moore, Jane S Green, Yanli Fan, et al.
American Journal of Human Genetics|March 4, 2008
Arrhythmogenic right ventricular cardiomyopathy type 5 is a fully penetrant, lethal arrhythmic disorder caused by a missense mutation in the TMEM43 geneNancy D Merner, Kathy A Hodgkinson, Annika F M Haywood, et al.
American Journal of Kidney Diseases : the Official Journal of the National Kidney Foundation|November 20, 2012
Hemoglobin stability in patients with anemia, CKD, and type 2 diabetes: an analysis of the TREAT (Trial to Reduce Cardiovascular Events With Aranesp Therapy) placebo armHicham Skali, Julie Lin, Marc A Pfeffer, et al.
Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association|April 25, 2023
Vadadustat for treatment of anemia in patients with dialysis-dependent chronic kidney disease receiving peritoneal dialysisMark J Sarnak, Rajiv Agarwal, Neil Boudville, et al.
The Journal of Clinical Endocrinology and Metabolism|October 11, 2013
The clinical course of treated hyperparathyroidism among patients receiving hemodialysis and the effect of cinacalcet: the EVOLVE trialPatrick S Parfrey, Glenn M Chertow, Geoffrey A Block, et al.
The New England Journal of Medicine|November 6, 2012
Effect of cinacalcet on cardiovascular disease in patients undergoing dialysis, Glenn M Chertow, Geoffrey A Block, et al.
Hemodialysis International. International Symposium on Home Hemodialysis|November 14, 2015
Cinacalcet, dialysate calcium concentration, and cardiovascular events in the EVOLVE trialPatrick H Pun, Safa Abdalla, Geoffrey A Block, et al.
Journal of the American Heart Association|November 19, 2014
Effects of cinacalcet on atherosclerotic and nonatherosclerotic cardiovascular events in patients receiving hemodialysis: the EValuation Of Cinacalcet HCl Therapy to Lower CardioVascular Events (EVOLVE) trialDavid C Wheeler, Gerard M London, Patrick S Parfrey, et al.
International Journal of Cancer|December 21, 2010
Cancer risks for monoallelic MUTYH mutation carriers with a family history of colorectal cancerAung Ko Win, Sean P Cleary, James G Dowty, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 6, 2005
High frequency of hereditary colorectal cancer in Newfoundland likely involves novel susceptibility genesMichael O Woods, Angela J Hyde, Fiona K Curtis, et al.
Pageof 16